A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN SC IN COMBINATION WITH PERJETA AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2−POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY RECURRENT)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Dec 2017
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Registrational
- Acronyms MetaPHER
- Sponsors Roche
- 12 Apr 2017 Planned End Date changed from 1 Feb 2019 to 19 Mar 2019.
- 12 Apr 2017 Planned primary completion date changed from 1 Feb 2019 to 19 Mar 2019.
- 12 Apr 2017 Status changed from recruiting to active, no longer recruiting.